Propanc Biopharma (NASDAQ:PPCB) Releases Earnings Results

Propanc Biopharma (NASDAQ:PPCB) issued its quarterly earnings data on Friday. The company reported $6.13 EPS for the quarter, FiscalAI reports.

Propanc Biopharma Stock Up 4.7%

Shares of NASDAQ PPCB traded up $0.03 during midday trading on Friday, hitting $0.63. 384,106 shares of the company’s stock were exchanged, compared to its average volume of 526,668. Propanc Biopharma has a 12-month low of $0.56 and a 12-month high of $52.50. The business’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.84.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Propanc Biopharma declared that its Board of Directors has approved a stock buyback plan on Thursday, June 11th that permits the company to repurchase $5.00 million in shares. This repurchase authorization permits the company to repurchase up to 162.3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Propanc Biopharma Company Profile

Propanc Biopharma, Inc is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis.

Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers.